PTC Therapeutics is seeking participants for its MIT-E Study, looking at whether an investigational drug (PTC-743 also known as EPI-743) can reduce the number of seizures in children and teens who have mitochondrial disease with associated Epilepsy.  

Participants must:

- Be under 18 years old;

- Have inherited mitochondrial disease with associated Epilepsy and symptoms that have been ongoing for at least six months; and

- Have had at least six seizures in the last four weeks.  

Learn more here.

Lindsey Klingensmith

Executive Director

Public relation awesomeness.

Latest News

MITO Families needed for new survey re: COVID19 vaccine

NIH seeking to better understand evolving pandemic and i's impact on children with Mitochondrial Disease

Lindsey Klingensmith
January 29, 2021
Learn More
NIH launches new study: Mitochondrial Disease During the COVID19 Pandemic

The goal of the study is to learn more about the role of viral infection and biomarkers of immunity in mitochondrial disease during the COVID19 pandemic.

Lindsey Klingensmith
November 20, 2020
Learn More